Fresh analysis indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who stop traditional lifestyle regimens.
Findings released in a prominent health publication points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"People using these treatments must be aware of the danger of rapid rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of regain implies a return to original mass within about 18 months.
Weighing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.
Scientists note that people who lose weight through diet and exercise generally see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists propose the way of the drugs accounts for the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than the body's typical production might result in the body to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means hunger is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
Medical guidelines advise the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the significant potential of relapse, the treatment is often life-long.
This perspective is reinforced by drug manufacturers, who say that the results "underscore the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have stopped the jabs report a powerful resurgence of hunger.
"It felt as if a trigger activating and I was suddenly starving," said a patient.
This difficulty is compounded if users have not established sustainable lifestyle or habit changes during treatment.
Widespread Interest
Survey data suggest that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, experts caution that while these medications are effective agents for weight loss, they are not a standalone solution and long-term success hinges on integrated behavioural support.
